Analysis regarding risk of stroke for 85 different proteins using a meta-analysis of individual data from the PIVUS study and ULSAM.
| Protein | Age, sex and study adjusted | Multiple adjusted | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) | 1.57 (1.41 to 1.76) | <0.0001 | 1.57 (1.39 to 1.76) | <0.0001 |
| Fibroblast growth factor 23 (FGF-23) | 1.26 (1.14 to 1.4) | <0.0001 | 1.18 (1.06 to 1.32) | 0.0025 |
| Interleukin-6 (IL-6) | 1.26 (1.13 to 1.4) | <0.0001 | 1.25 (1.11 to 1.4) | 0.0001 |
| Fatty acid-binding protein 4 (FABP4) | 1.32 (1.16 to 1.5) | <0.0001 | 1.22 (1.05 to 1.43) | 0.0116 |
| Growth differentiation factor 15 (GDF-15) | 1.27 (1.13 to 1.44) | 0.0001 | 1.25 (1.09 to 1.44) | 0.0018 |
| T-cell immunoglobulin and mucin domain 1 (TIM-1) | 1.26 (1.12 to 1.43) | 0.0002 | 1.23 (1.07 to 1.4) | 0.0028 |
| Adrenomedullin (AM) | 1.27 (1.11 to 1.44) | 0.0004 | 1.22 (1.06 to 1.4) | 0.0044 |
Only the proteins with a p Value <0.000588 (Bonferroni adjustment) are shown. HR and 95% CI are given for two levels of adjustments; age, sex and study and multiple cardiovascular risk factors (study, age, sex, systolic blood pressure, BMI, diabetes, prevalent myocardial infarction, heart failure and current smoking). The HR refers to a doubling of the protein concentration.
No significant interactions between protein levels and study regarding incident AF were found.
AF, atrial fibrillation; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; ULSAM, Uppsala Longitudinal Study of Adult Men.